Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Table 4 Treatment emergent adverse effects in the study participants

Characteristic	Placebo (n = 65)	Rasagiline 1 mg (n = 65)
Patients with TEAEs	30 (46.2)	27 (41.5)
SAEs	4 (6.2)	0 (0)
TEAEs leading to withdrawal	5 (7.7)	3 (4.6)
Nervous system disorder	10 (15.4)	13 (20.0)
Bradykinesia	0 (0)	1 (1.5)
Dizziness	3 (4.6)	3 (4.6)
Headache	0 (0)	2 (3.1)
Parkinson’s disease^a	4 (6.2)	5 (7.7)
Poor quality sleep	0 (0)	1 (1.5)
Somnolence	0 (0)	2 (3.1)
Speech disorder	1 (1.5)	0 (0)
Tremor	3 (4.6)	3 (4.6)
Gastrointestinal disorders	7 (10.8)	5 (7.7)
Abdominal discomfort	2 (3.1)	0 (0)
Constipation	0 (0)	1 (1.5)
Diarrhea	1 (1.5)	2 (3.1)
Dry mouth	1 (1.5)	1 (1.5)
Gastric dilation	1 (1.5)	0 (0)
Nausea	1 (1.5)	0 (0)
Psychiatric disorders	2 (3.1)	2 (3.1)
Hallucination	0 (0)	1 (1.5)
Insomnia	1 (1.5)	1 (1.5)
Major depression	1 (1.5)	0 (0)
Eye disorders	1 (1.5)	2 (3.1)

Data are n (%). TEAE, treatment-emergent adverse event. SAE, serious adverse event
^aParkinson’s disease means the worsening or progression of Parkinson’s disease

ISSN: 2047-9158